114 related articles for article (PubMed ID: 16211243)
1. Deregulation of estrogen induced telomerase activity in tamoxifen-resistant breast cancer cells.
Park WC; Liu H; Macgregor Schafer J; Jordan VC
Int J Oncol; 2005 Nov; 27(5):1459-66. PubMed ID: 16211243
[TBL] [Abstract][Full Text] [Related]
2. Tamoxifen regulates human telomerase reverse transcriptase (hTERT) gene expression differently in breast and endometrial cancer cells.
Wang Z; Kyo S; Maida Y; Takakura M; Tanaka M; Yatabe N; Kanaya T; Nakamura M; Koike K; Hisamoto K; Ohmichi M; Inoue M
Oncogene; 2002 May; 21(22):3517-24. PubMed ID: 12032853
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of PKCalpha is required to impart estradiol inhibition and tamoxifen-resistance in a T47D human breast cancer tumor model.
Lin X; Yu Y; Zhao H; Zhang Y; Manela J; Tonetti DA
Carcinogenesis; 2006 Aug; 27(8):1538-46. PubMed ID: 16513679
[TBL] [Abstract][Full Text] [Related]
4. An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells.
Aesoy R; Sanchez BC; Norum JH; Lewensohn R; Viktorsson K; Linderholm B
Mol Cancer Res; 2008 Oct; 6(10):1630-8. PubMed ID: 18922978
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a receptor-negative, hormone-nonresponsive clone derived from a T47D human breast cancer cell line kept under estrogen-free conditions.
Murphy CS; Pink JJ; Jordan VC
Cancer Res; 1990 Nov; 50(22):7285-92. PubMed ID: 2224859
[TBL] [Abstract][Full Text] [Related]
6. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
[TBL] [Abstract][Full Text] [Related]
7. Rapid development of tamoxifen-stimulated mutant p53 breast tumors (T47D) in athymic mice.
Schafer JM; Lee ES; O'Regan RM; Yao K; Jordan VC
Clin Cancer Res; 2000 Nov; 6(11):4373-80. PubMed ID: 11106256
[TBL] [Abstract][Full Text] [Related]
8. Gene expression changes during the development of estrogen-independent and antiestrogen-resistant growth in breast cancer cell culture models.
Pennanen PT; Sarvilinna NS; Ylikomi TJ
Anticancer Drugs; 2009 Jan; 20(1):51-8. PubMed ID: 19343000
[TBL] [Abstract][Full Text] [Related]
9. The effect of the phytoestrogens genistein, daidzein, and equol on the growth of tamoxifen-resistant T47D/PKC alpha.
Tonetti DA; Zhang Y; Zhao H; Lim SB; Constantinou AI
Nutr Cancer; 2007; 58(2):222-9. PubMed ID: 17640169
[TBL] [Abstract][Full Text] [Related]
10. Effects of estrogen and tamoxifen on the regulation of dihydrofolate reductase gene expression in a human breast cancer cell line.
Levine RM; Rubalcaba E; Lippman ME; Cowan KH
Cancer Res; 1985 Apr; 45(4):1644-50. PubMed ID: 3978632
[TBL] [Abstract][Full Text] [Related]
11. EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity.
Lu M; Miller KD; Gokmen-Polar Y; Jeng MH; Kinch MS
Cancer Res; 2003 Jun; 63(12):3425-9. PubMed ID: 12810680
[TBL] [Abstract][Full Text] [Related]
12. Effects of tamoxifen on telomerase activity in breast carcinoma cell lines.
Aldous WK; Marean AJ; DeHart MJ; Matej LA; Moore KH
Cancer; 1999 Apr; 85(7):1523-9. PubMed ID: 10193942
[TBL] [Abstract][Full Text] [Related]
13. Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth.
Britton DJ; Hutcheson IR; Knowlden JM; Barrow D; Giles M; McClelland RA; Gee JM; Nicholson RI
Breast Cancer Res Treat; 2006 Mar; 96(2):131-46. PubMed ID: 16261397
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia and estrogen receptor profile influence the responsiveness of human breast cancer cells to estradiol and antiestrogens.
Coradini D; Pellizzaro C; Speranza A; Daidone MG
Cell Mol Life Sci; 2004 Jan; 61(1):76-82. PubMed ID: 14704855
[TBL] [Abstract][Full Text] [Related]
15. Altered phenotypic characteristics of T47d human breast cancer cells after prolonged growth in estrogen-deficient medium.
Fernandez P; Wilson C; Hoivik D; Safe SH
Cell Biol Int; 1998; 22(9-10):623-33. PubMed ID: 10452832
[TBL] [Abstract][Full Text] [Related]
16. Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients.
Holm C; Rayala S; Jirström K; Stål O; Kumar R; Landberg G
J Natl Cancer Inst; 2006 May; 98(10):671-80. PubMed ID: 16705121
[TBL] [Abstract][Full Text] [Related]
17. Extranuclear ERα is associated with regression of T47D PKCα-overexpressing, tamoxifen-resistant breast cancer.
Perez White B; Molloy ME; Zhao H; Zhang Y; Tonetti DA
Mol Cancer; 2013 May; 12():34. PubMed ID: 23634843
[TBL] [Abstract][Full Text] [Related]
18. Clusterin: a potential target for improving response to antiestrogens.
Toffanin S; Daidone MG; Miodini P; De Cecco L; Gandellini P; Cappelletti V
Int J Oncol; 2008 Oct; 33(4):791-8. PubMed ID: 18813793
[TBL] [Abstract][Full Text] [Related]
19. Development of cross-resistance to tamoxifen in raloxifene-treated breast carcinoma cells.
Gao ZO; Gao ZP; Fields JZ; Boman BM
Anticancer Res; 2002; 22(3):1379-83. PubMed ID: 12168814
[TBL] [Abstract][Full Text] [Related]
20. Mifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor-expressing, antiestrogen-resistant breast cancer cells.
Gaddy VT; Barrett JT; Delk JN; Kallab AM; Porter AG; Schoenlein PV
Clin Cancer Res; 2004 Aug; 10(15):5215-25. PubMed ID: 15297425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
